Barbara Elashoff.

This limitation ought to be taken into account by clinicians when they consider the use of gene-expression profiling in the care of their patients. The low projected event rates and the limited number of available patients necessitated the decision of a wide noninferiority margin. The trial’s decreased power was reflected in a relatively wide self-confidence interval that does not exclude the possibility of a 33 percent reduction in primary event rates or of a 68 percent increase among patients in the gene-profiling group. Our composite final result was chosen to add both clinically overt rejection and the possible implications of undiagnosed rejection.Few trials have attempted behavioral weight-loss strategies in the primary care setting, and none have implemented interventions identical to those tested in the charged power trial. Wadden and Tsai conducted a systematic review of the literature on this topic.8 Of the 10 trials recognized, 4 trials tested the use of PCP counseling alone, 3 tested PCP counseling with pharmacotherapy, and 3 tested a collaborative approach in which the intervention was shipped by care providers other than PCPs. The results of these trials were inconsistent, and most of these had one or more limitations .21-23 Our trial has restrictions. Its duration, although than that of several weight-loss trials longer, was only 24 months.